Piramal Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Piramal Pharma's recent operational performance indicates a strong start to FY27, with broad-based growth across its CDMO, Complex Hospital Generics (CHG), and India Consumer Healthcare (ICH) segments. Management's cautious optimism reflects a disciplined approach to revenue growth, maintaining guidance in the early-to-mid teens despite challenges in converting RFPs into commercial orders. The strategic focus on expanding ADC manufacturing and sterile injectables is expected to enhance margins, targeting 25% by FY30. Vista's financial outlook aligns with this trajectory, forecasting stable margins and a recovery in revenue growth, supported by operational leverage and cost optimization. However, competitive pressures in the CHG segment and potential delays in order conversions remain critical watchpoints. The industry context, characterized by expanding opportunities for Indian CDMOs, further supports Piramal's growth potential, although raw material supply constraints could pose challenges. Over the next 12-24 months, key opportunities include scaling the CDMO business and leveraging premiumization strategies, while headwinds may arise from execution risks and inflationary pressures
Why We Like This Stock
- Broad-based growth across CDMO, CHG, and ICH segments indicates operational strength
- Strategic focus on higher-margin complex products and capacity expansion supports margin improvement
- Industry trends favoring Indian CDMOs provide a favorable backdrop for growth
Things To Watch Out For
- Delays in converting RFPs into commercial orders could hinder revenue growth
- Competitive intensity in the CHG segment poses risks to market share
- Inflationary pressures and operational cost increases may impact profitability
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 8,171 | 9,151 | 8,869 | 9,865 | 11,132 |
| Profit Before Tax (Cr.) | 238 | 405 | 20 | 416 | 467 |
| PBT Margin | 2.9% | 4.4% | 22.6% | 4.2% | 4.2% |
| Net Profit (Cr.) | 18 | 111 | -261 | 312 | 350 |
| Earnings Per Share | 0.1 | 0.8 | -2.0 | 2.4 | 2.6 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Goldman Sachs | ▲ Buy | 250 | 31-Jul-2026 |
| HDFC Securities | ▲ Buy | 240 | 30-Jul-2026 |
| ICICI Securities | ▲ Buy | 245 | 31-Jul-2026 |
| Jeffries | ▲ Buy | 190 | 30-Apr-2026 |
| Motilal Oswal | ▲ Buy | 230 | 30-Jul-2026 |
Company Overview
Show Company Profile
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. The company was incorporated in 2020 and is based in Mumbai, India.